Abstract
Kv10.1 has recently become generally accepted as a promising cancer target, as it is ectopically expressed in the majority of solid tumors. Due to its cell-surface accessibility, Kv10.1 has a strong potential for tumor treatment and diagnosis. Given that its mode of action is likely independent of conventional cancer pathways such as tyrosine kinases, KV10.1 opens a novel window for treating cancer. In this review we will give an overview of the current status of data linking Kv10.1 to cancer, and propose techniques that could exploit Kv10.1s properties for the management of cancer
Keywords: ADEPT, astemizole, cancer diagnosis, cancer prognosis, eag1, ether a go-go, imipramine, immunotherapy, immunotargeted therapy, KCNH1, KV10.1, potassium channel, tumor therapy
Current Medicinal Chemistry
Title: Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Volume: 19 Issue: 5
Author(s): L.A. Pardo, D. Gomez-Varela, F. Major, K. Sansuk, R. Leurs, B.R. Downie, L.F. Tietze and W. Stuhmer
Affiliation:
Keywords: ADEPT, astemizole, cancer diagnosis, cancer prognosis, eag1, ether a go-go, imipramine, immunotherapy, immunotargeted therapy, KCNH1, KV10.1, potassium channel, tumor therapy
Abstract: Kv10.1 has recently become generally accepted as a promising cancer target, as it is ectopically expressed in the majority of solid tumors. Due to its cell-surface accessibility, Kv10.1 has a strong potential for tumor treatment and diagnosis. Given that its mode of action is likely independent of conventional cancer pathways such as tyrosine kinases, KV10.1 opens a novel window for treating cancer. In this review we will give an overview of the current status of data linking Kv10.1 to cancer, and propose techniques that could exploit Kv10.1s properties for the management of cancer
Export Options
About this article
Cite this article as:
Pardo L.A., Gomez-Varela D., Major F., Sansuk K., Leurs R., Downie B.R., Tietze L.F. and Stuhmer W., Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy, Current Medicinal Chemistry 2012; 19 (5) . https://dx.doi.org/10.2174/092986712798992011
DOI https://dx.doi.org/10.2174/092986712798992011 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Fe3O4 Nanoparticles Mediated Synthesis of Novel Isatin-dihydropyrimidinone Hybrid Molecules as Antioxidant and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity
Letters in Drug Design & Discovery New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets Histopathology, Immunohistochemistry and Molecular Biology of Follicular Epithelium-Derived Pediatric Thyroid Carcinomas
Current Pediatric Reviews Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer
Current Pharmaceutical Design Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Antiangiogenic Therapy
Current Pharmaceutical Design Drug Delivery Systems for Prevention and Treatment of Osteoporotic Fracture
Current Drug Targets Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal